IL2 and neoplasm: The efficient tumor cell lysis induced by these mAbs was explained by the increased activation of lymphocytes co-cultured with tumor cells, leading to enhanced levels of IFN-γ and IL-2 release, with respect to those treated with atezolizumab and ipilimumab.